Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Customs union has not helped UK firms, economist says
Gerard Lyons tells CNBC there is too much fear about leaving the EU without a deal.
Shari Redstone launches formal auction of National Amusements: Report
CNBC’s Andrew Ross Sorkin reports on the latest news.
Housing demand is still outpacing supply, says Evercore ISI’s Kim
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Homebuilders have outperformed, and Evercore ISI homebuilder analyst Stephen King joins ‘The Exchange’ to explain why. 05:41 Fri, May 27 20221:48 PM EDT
Dennis Unkovic breaks down the impact of the Taiwan elections on China relations
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dennis Unkovic, Meyer, Unkovic & Scott partner, joins ‘Power Lunch’ to discuss the impact of the Taiwan elections on the global markets and more.
Cramer’s Mad Dash: Chewy
CNBC’s Jim Cramer delivers his daily Mad Dash.
CNBC Pro Talks: Top strategists and stock pickers share their 2024 market playbook
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The S&P 500 ended 2023 with a bang, up 24% on the year despite persistent recession warnings, a regional banking crisis, widespread tech layoffs, and ‘higher-for-longer’ interest rates. Can the stock market momentum continue into 2024? Can the rally broaden out past…
